Gold nanoparticles are once again in the drug delivery spotlight as MIT scientists have discovered a mechanism by which the particles enter cells and could thus act as better drug carriers.
Robotics company Boston Dynamics and MIT are teaming up to develop the next generation of robots. The duo developed a new composite material that can quickly transform from a rigid state into a softer one by softening its joints with heat.
A new contraceptive implant developed by Lexington, MA-based MicroCHIPS could give women remote-controlled access to their hormone administration, offering up to 16 years of specifically dosed delivery and thus more authority over their birth control regimens.
Researchers are attempting to develop methods of sneaking drugs past bacteria's external defense system by delivering therapies via molecules that bacteria secrete to find and obtain iron.
A team from the Massachusetts Institute of Technology is a finalist for the 2014 Hult Prize after developing a simple wound-therapy device to improve the lives of those lacking access to adequate medical care.
The industry is looking for new ways to manufacture drugs which will save it money and Aprecia thinks it has found it in a method that it has licensed from MIT: 3-D printing.
Scientists at MIT have engineered a one-two punch for cancer that carries two drugs at a time and has been shown to shrink lung and breast tumors in mice. While other nanoparticles have carried multiple drugs, this one makes use of a specific timing mechanism to get the most out of each treatment.
One of the chief drawbacks of RNA interference therapies so far has been the difficulty of delivering small interfering RNA to cells outside the liver. That's why a newly reported breakthrough in delivering siRNA to endothelial cells in the lung and other organs is a big deal.
George Scangos, CEO of biotech powerhouse Biogen Idec, and David Page, director of MIT's Whitehead Institute for Biomedical Research, have made a $5.3 million handshake, the Boston Globe reports, as the two institutions plan to collaborate on early-phase development.
Last night I was a guest lecturer at an MIT class of biomedical PhD candidates. One of the professors had asked me to come and provide my take on covering biotech news, and I took it on for largely selfish reasons.